I Biology Patent Engine

i_Biology Patent Engine: (i-BPE)

by Diane Ludin
"A patent is a type of property right. It gives the patent holder the right, for a limited time, to exclude others from making, using, offering to sell, selling, or importing into the United States the subject matter that is within the scope of protection granted by the patent." - U.S. Patent Office

i-BPE is an open gene patent machine.
i-BPE will raid trans-corporate bio-pirate silos.
i-BPE agents will offer trans-corporate DNA play, for non-governmental ownership.
i-BPE will filter the gene market's esoteric intelligence networks for aggressive take-over by i-BPE agents.
i-BPE gene patents will return bio-rights to non-governmental, cultural agents for revision.
i-BPE is an open gene project. i-BPE is a counter-market-objectivity tool.
i-BPE is a patent the patent action.

Why do we need an i-Biology Patent Engine (i-BPE)?

Against the backdrop of the September 11th terrorist attacks in the US, the anthrax crisis has raised highly controversial issues related to intellectual property rights. By waiving the Bayer patent, the US would be able to approach other companies to manufacture greater and cheaper supplies of ciprofloxacin, as the drug is known generically. This would ease concerns that Bayer might not be able to produce enough ciprofloxacin to counter widespread anthrax attacks. However, any move to override the Bayer patent would represent a serious policy U-turn for the Bush administration, which the administration is unwilling to do. For them profit is more important then public health. Just last year, the world witnessed heated debate on the patent controversy when the Pharmaceutical Manufacturers' Association of South Africa (a WTO member) took the South African government to court to prevent it from importing cheaper versions of patented AIDS drugs. Under tremendous pressure from health activists around the world, the drug companies and WTO unconditionally dropped their lawsuit against the South African government. How will the i-Biology Patent Engine function (i-BPE)? The i-Biology Patent Engine (i-BPE) will allow on-line communities to revise and archive new patents. (i-BPE) software opens the source of current trans-corporate patents, by offering users the means to assemble their own inventions by recycling existing ones. The real patents and the i-BPE patents will be placed in a data repository and offered to the end users for further remixing. The i-Biology Patent Engine (i-BPE) can then be downloaded as a file. The file will be designed to mimic existing patent forms. A few choice biotech patents targeted for remixing:

Soybean Variety 92B6 - U. S. Patent 6,346,657

Method to obtain male sterile plants - U. S. Patent 6,344,602

Method to obtain female sterile plants - U. S. Patent 6,297,426 B1

	i_Biology Patent Engine: (i-BPE) by Diane Ludin "A patent is a type of property right. It gives the patent holder the right, for a limited time, to exclude others from making, using, offering to sell, selling, or importing into the United States the subject matter that is within the scope of protection granted by the patent." - U.S. Patent Office
	i-BPE is an open gene patent machine. i-BPE will raid trans-corporate bio-pirate silos. i-BPE agents will offer trans-corporate DNA play, for non-governmental ownership. i-BPE will filter the gene market's esoteric intelligence networks for aggressive take-over by i-BPE agents. i-BPE gene patents will return bio-rights to non-governmental, cultural agents for revision. i-BPE is an open gene project. i-BPE is a counter-market-objectivity tool. i-BPE is a patent the patent action.
	Why do we need an i-Biology Patent Engine (i-BPE)? Against the backdrop of the September 11th terrorist attacks in the US, the anthrax crisis has raised highly controversial issues related to intellectual property rights. By waiving the Bayer patent, the US would be able to approach other companies to manufacture greater and cheaper supplies of ciprofloxacin, as the drug is known generically. This would ease concerns that Bayer might not be able to produce enough ciprofloxacin to counter widespread anthrax attacks. However, any move to override the Bayer patent would represent a serious policy U-turn for the Bush administration, which the administration is unwilling to do. For them profit is more important then public health. Just last year, the world witnessed heated debate on the patent controversy when the Pharmaceutical Manufacturers' Association of South Africa (a WTO member) took the South African government to court to prevent it from importing cheaper versions of patented AIDS drugs. Under tremendous pressure from health activists around the world, the drug companies and WTO unconditionally dropped their lawsuit against the South African government. How will the i-Biology Patent Engine function (i-BPE)? The i-Biology Patent Engine (i-BPE) will allow on-line communities to revise and archive new patents. (i-BPE) software opens the source of current trans-corporate patents, by offering users the means to assemble their own inventions by recycling existing ones. The real patents and the i-BPE patents will be placed in a data repository and offered to the end users for further remixing. The i-Biology Patent Engine (i-BPE) can then be downloaded as a file. The file will be designed to mimic existing patent forms. A few choice biotech patents targeted for remixing:
	Soybean Variety 92B6 - U. S. Patent 6,346,657
	Method to obtain male sterile plants - U. S. Patent 6,344,602
	Method to obtain female sterile plants - U. S. Patent 6,297,426 B1